NYSEARCA:XPH SPDR S&P Pharmaceuticals ETF (XPH) Price, Holdings, & News → The asset beating inflation by 4x (From Colonial Metals) (Ad) Free XPH Stock Alerts $39.72 -0.04 (-0.10%) (As of 05:13 PM ET) Add Compare Share Share Today's Range$39.71▼$39.9950-Day Range$39.09▼$42.0152-Week Range$34.67▼$45.62Volume38,237 shsAverage Volume37,338 shsMarket Capitalization$192.64 millionAssets Under Management$188.95 millionDividend Yield1.69%Net Expense Ratio0.35% Stock AnalysisStock AnalysisChartHeadlinesHoldingsOwnershipRatingsStock AnalysisChartHeadlinesHoldingsOwnershipRatings Get SPDR S&P Pharmaceuticals ETF alerts: Email Address About SPDR S&P Pharmaceuticals ETFSPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Fund invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, the Fund may invest in equity securities that are not included in the Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds. The Pharmaceuticals Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.Read More XPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XPH ETF News HeadlinesMarch 30, 2024 | finance.yahoo.comSPDR S&P Pharmaceuticals ETF (XPH)March 28, 2024 | seekingalpha.comXPH: A More Balanced Way To Get Exposure To PharmaceuticalsJune 18, 2024 | Colonial Metals (Ad)The asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire investors are buying right along with them. Even Warren Buffett put over $500 million into gold. And with the help of a tax and penalty-free "Trump Loophole, " these investors are investing retirement into gold and other precious metals without having to put up any of their own cash. In our Free Precious Metals Guide, we reveal all the details on how the rich use this loophole to protect and growth their retirement wealth in any economy…and show you how you can use it too.February 16, 2024 | wsj.comSPDR S&P Pharmaceuticals ETFFebruary 5, 2024 | usatoday.comS&P 500 (SPX) today: Catalent Inc is a top mover, up 10%December 23, 2023 | benzinga.comSPDR S&P Pharmaceuticals ETF (ARCA:XPH), Quotes and News SummaryDecember 18, 2023 | msn.comSPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.1744November 6, 2023 | marketwatch.comWhy the S&P 500 ETF’s rare triple ‘gap ups’ isn’t a buy signalJune 18, 2024 | Colonial Metals (Ad)The asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire investors are buying right along with them. Even Warren Buffett put over $500 million into gold. And with the help of a tax and penalty-free "Trump Loophole, " these investors are investing retirement into gold and other precious metals without having to put up any of their own cash. In our Free Precious Metals Guide, we reveal all the details on how the rich use this loophole to protect and growth their retirement wealth in any economy…and show you how you can use it too.October 29, 2023 | investing.comXPH ETF Stock Price HistorySee More Headlines Receive XPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SPDR S&P Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerSSgA Fund NameSPDR S&P Pharmaceuticals ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:XPH Inception Date6/19/2006 Fund ManagerMichael Feehily, Karl Schneider, Keith Richardson Webwww.spdrs.com Phone+1-617-6644738Fund Focus Asset ClassEquity BenchmarkS&P Pharmaceuticals Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings42 Fund Statistics Assets Under Management$188.95 million Average Daily Volume$23,583.80 Discount/Premium-0.02% Administrator, Advisor and Custodian AdministratorSSgA Funds Management, Inc. AdvisorSSgA Funds Management, Inc. CustodianState Street Bank and Trust Company DistributorState Street Global Advisors Funds Distributors, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerCitadel Options OptionableOptionable Options Volume1 Put Options1 Call Options1 Short Interest362,200 shs Miscellaneous Outstanding Shares4,850,000Beta0.87 Creation Unit50,000 Creation Fee$250.00 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Ad Porter & CompanyKiss of death from Joe BidenBiden cannot lose this election. A bombshell new documentary exposes how the D.C establishment has engineered an “electoral failsafe” that all but guarantees Democratic victory… not just in 2024 but every future election.I have uncovered a bombshell that changes everything… and threatens everything. SPDR S&P Pharmaceuticals ETF ExpensesTypeXPHHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.35%0.56%0.54%0.51%0.51%Other Expenses0.00%0.33%0.50%0.59%0.54%Total Expense0.35%0.70%0.70%0.74%0.71%Fee Waiver0.00%-0.45%-0.55%-0.69%-0.60%Net Expense0.35%0.61%0.60%0.58%0.58% SPDR S&P Pharmaceuticals ETF (XPH) Holdings & ExposureTop 10 XPH HoldingsOrganon & Co.(NYSE:OGN)Holding Weight: 5.56%Eli Lilly and Company(NYSE:LLY)Holding Weight: 5.23%Elanco Animal Health(NYSE:ELAN)Holding Weight: 5.17%Pfizer(NYSE:PFE)Holding Weight: 5.16%Merck & Co., Inc.(NYSE:MRK)Holding Weight: 4.99%Intra-Cellular Therapies(NASDAQ:ITCI)Holding Weight: 4.86%Axsome Therapeutics(NASDAQ:AXSM)Holding Weight: 4.85%Catalent(NYSE:CTLT)Holding Weight: 4.61%Corcept Therapeutics(NASDAQ:CORT)Holding Weight: 4.60%Zoetis(NYSE:ZTS)Holding Weight: 4.54%XPH Sector ExposureXPH Industry ExposureFull Holdings Details Key ExecutivesJames E. Ross (Age 52)President, Trustee Peter A. Ambrosini (Age 69)Chief Compliance Officer Michael P. Riley (Age 44)Vice President Gary L. French (Age 64)Treasurer John W. Clark (Age 46)Assistant Treasurer Matthew W. Flaherty (Age 42)Assistant Treasurer Chad C. Hallett (Age 47)Assistant Treasurer of Street tracks series trust Mary Moran Zeven (Age 52)Secretary Scott M. Zoltowski (Age 44)Assistant Secretary Dave KellyIndependent TrusteeMore ExecutivesSimilar ETFsInvesco S&P SmallCap Health Care ETFNASDAQ:PSCHDirexion Daily Healthcare Bull 3x SharesNYSEARCA:CUREInvesco Dorsey Wright Healthcare Momentum ETFNASDAQ:PTHSPDR S&P Health Care Equipment ETFNYSEARCA:XHEInvesco Biotechnology & Genome ETFNYSEARCA:PBEInstitutional OwnershipHealthcare of Ontario Pension Plan Trust FundSold 11,000 shares on 5/14/2024Ownership: 1.278%Kingsview Wealth Management LLCBought 115,712 shares on 5/9/2024Ownership: 2.966%Envestnet Portfolio Solutions Inc.Bought 10,534 shares on 5/6/2024Ownership: 1.176%BNP Paribas Financial MarketsBought 570 shares on 5/1/2024Ownership: 1.180%PNC Financial Services Group Inc.Sold 11,427 shares on 3/22/2024Ownership: 0.528%View All Institutional Transactions XPH ETF - Frequently Asked Questions How have XPH shares performed in 2024? SPDR S&P Pharmaceuticals ETF's stock was trading at $41.62 on January 1st, 2024. Since then, XPH shares have decreased by 4.5% and is now trading at $39.73. View the best growth stocks for 2024 here. What does XPH invest in? SPDR S&P Pharmaceuticals ETF is a equity fund issued by SSgA. XPH focuses on health care investments and follows the S&P Pharmaceuticals Index. The fund's investments total to approximately $188.95 million assets under management. What stocks does SPDR S&P Pharmaceuticals ETF hold? XPH invests in 42 holdings. Some of the stocks in their portfolio include Organon & Co. (OGN), Eli Lilly and Company (LLY), Elanco Animal Health (ELAN), Pfizer (PFE), Merck & Co., Inc. (MRK), Intra-Cellular Therapies (ITCI), Axsome Therapeutics (AXSM), Catalent (CTLT), Corcept Therapeutics (CORT) and Zoetis (ZTS). What is the management fee for SPDR S&P Pharmaceuticals ETF? SPDR S&P Pharmaceuticals ETF's management fee is 0.35% and has no other recorded expenses or fee waivers. The net expense ratio for XPH is 0.35%. What other stocks do shareholders of SPDR S&P Pharmaceuticals ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other SPDR S&P Pharmaceuticals ETF investors own include Pfizer (PFE), Bank of America (BAC), Micron Technology (MU), Broadcom (AVGO), Chevron (CVX), DocuSign (DOCU), SPDR Gold Shares (GLD), International Business Machines (IBM), JPMorgan Chase & Co. (JPM) and AT&T (T). Who are SPDR S&P Pharmaceuticals ETF's major shareholders? SPDR S&P Pharmaceuticals ETF's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Kingsview Wealth Management LLC (2.97%), Healthcare of Ontario Pension Plan Trust Fund (1.28%), BNP Paribas Financial Markets (1.18%) and Envestnet Portfolio Solutions Inc. (1.18%). How do I buy shares of SPDR S&P Pharmaceuticals ETF? Shares of XPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEARCA:XPH) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | Sponsoredwhy 99.94% won’t make you moneyI believe there's only 5-7 stocks that you should trade in 2024. But here's the catch…because there's alway...Prosper Trading Academy | SponsoredThe Hidden Anchor Investment of the Elite RevealedThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because sav...Colonial Metals | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Pharmaceuticals ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.